| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a98cb1b197f761c87cd3caf32bc247e2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| filingDate |
2016-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f516af6ccb29a911b6bcbec052a0d676 |
| publicationDate |
2021-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MY-185785-A |
| titleOfInvention |
Novel crystal of uracil compound |
| abstract |
The present invention provides a crystal that has preferable oral absorption and can be obtained with particularly preferable reproducibility. Provided is a crystal of (R)-N-(1-(3- (cyclopentyloxy)phenyl)ethyl)-3-((2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)methoxy)propane-1-sulfonamide. |
| priorityDate |
2015-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |